Regulation of bone mass in inflammatory diseases

Best Pract Res Clin Endocrinol Metab. 2022 Mar;36(2):101611. doi: 10.1016/j.beem.2021.101611. Epub 2021 Dec 28.

Abstract

Inflammation is among the major determinants of bone loss in chronic disease and aging. Bone metabolism is radically affected by inflammation with consequent bone loss and increased fracture risk. Various cytokines and mediators are involved in the pathogenesis of bone loss in inflammatory conditions. The present review has the aim of discussing the main pathways involved in the pathogenesis of bone loss in inflammatory diseases, focusing in particular on the Wnt system and its regulators. Literature review of studies published between inception to 2021 on osteoporosis and inflammation was conducted. I will discuss the epidemiology of osteoporosis and fractures in common inflammatory diseases. The molecular basis of bone loss related to inflammation will be discussed as well. Finally, the effects of various anti-inflammatory medications on bone metabolism will be reviewed.

Keywords: bone metabolism; disease modifying drugs; glucocorticoids; inflammation; osteoporosis; wnt system.

Publication types

  • Review

MeSH terms

  • Bone Density
  • Cytokines / pharmacology
  • Fractures, Bone* / etiology
  • Humans
  • Inflammation / complications
  • Osteoporosis* / epidemiology

Substances

  • Cytokines